Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that two important upcoming medical meetings have accepted its abstracts relating to the role of transient receptor potential ion channel activators to treat and prevent muscle cramping and spasms. The Company will present at:
1. The 31st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) held October 7-10, 2015 in Barcelona, Spain and
2. The 45th Annual Meeting of the Society for Neuroscience held October 17-21, 2015 in Chicago, IL.
“We look forward to these upcoming opportunities to share our clinical results with the scientific and medical communities regarding our proprietary approach to the treatment and prevention of muscle cramps and spasms,” noted Dr. Tom Wessel, Flex Pharma Chief Medical Officer. “With our ongoing and future clinical development programs, we expect to define the impact of this novel therapeutic approach harnessing chemical neurostimulation to treat and prevent cramps and spasms in different clinical settings such as nocturnal leg cramps, multiple sclerosis and motor neuron diseases such as ALS.”
The schedule and details for the abstracts and poster presentations are as follows:
|Date:||Thursday, October 8, 2015|
|Time:||15:45 – 17:00 in Barcelona, Spain|
|Abstract Title:||TRPV1 and TRPA1 activators reduce muscle cramping. Potential new treatment for MS symptoms|
|Meeting:||Society for Neuroscience|
|Date:||Tuesday, October 20, 2015|
|Time:||1:00 - 5:00 PM CST|
|Location:||McCormick Place, Hall A, Chicago, IL|
|Abstract Title:||Transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin-1 (TRPA1) activators reduce muscle cramping|
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers. In addition, the proprietary treatment has been demonstrated to prevent muscle cramps in an initial study of athletes participating in high intensity sports.
Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.